Pfizer Inc has received regulatory approval in the US for a personalised, or precision, medicine for lung cancer that demonstrated efficacy in a single-arm trial in both treatment naïve and previously treated patients with BRAF-V600E mutant metastatic non-small cell lung cancer. The medicine, Braftovi (encorafenib) and Mektovi (binimetinib), is a combination therapy that was first approved in 2018, but has since been updated. The newest approval includes two companion diagnostics that can identify BRAF V600E mutations in plasma or tumour tissue.
